KR930701201A - 면역반응성 화합물 - Google Patents
면역반응성 화합물Info
- Publication number
- KR930701201A KR930701201A KR1019920703408A KR920703408A KR930701201A KR 930701201 A KR930701201 A KR 930701201A KR 1019920703408 A KR1019920703408 A KR 1019920703408A KR 920703408 A KR920703408 A KR 920703408A KR 930701201 A KR930701201 A KR 930701201A
- Authority
- KR
- South Korea
- Prior art keywords
- compound according
- immunoreactive
- iga
- igm
- fragment
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Public Health (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP90201781 | 1990-07-03 | ||
EP90201781.3 | 1990-07-03 | ||
PCT/EP1991/001223 WO1992000763A1 (en) | 1990-07-03 | 1991-06-28 | Immunoreactive compound |
Publications (1)
Publication Number | Publication Date |
---|---|
KR930701201A true KR930701201A (ko) | 1993-06-11 |
Family
ID=8205056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019920703408A KR930701201A (ko) | 1990-07-03 | 1991-06-28 | 면역반응성 화합물 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0537222A1 (hu) |
JP (1) | JPH05507924A (hu) |
KR (1) | KR930701201A (hu) |
CA (1) | CA2086531A1 (hu) |
FI (1) | FI925804A (hu) |
HU (1) | HUT63343A (hu) |
WO (1) | WO1992000763A1 (hu) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9824632D0 (en) * | 1998-11-10 | 1999-01-06 | Celltech Therapeutics Ltd | Biological compounds |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3173342D1 (en) * | 1980-03-03 | 1986-02-13 | Milton David Goldenberg | Agent for tumor localization and therapy with labeled antibodies and antibody fragments |
CA1168150A (en) * | 1981-12-18 | 1984-05-29 | The Governors Of The University Of Alberta | Targeting conjugates of albumin and therapeutic agents |
NZ210867A (en) * | 1984-01-31 | 1989-01-06 | Litton Bionetics Inc | Tumour-specific monoclonal antibodies, production thereof and use |
EP0293524A1 (en) * | 1987-06-02 | 1988-12-07 | Vasocor | Atherosclerotic plaque immunoassay |
JPH01257263A (ja) * | 1987-06-19 | 1989-10-13 | Agouron Inst:The | Sm−d抗原、sm−d抗原のクローニングとsm−d抗原使用による播種性エリテマトーデの検出 |
ATE82136T1 (de) * | 1987-08-10 | 1992-11-15 | Miles Inc | Gereinigtes igm. |
US4937183A (en) * | 1988-02-03 | 1990-06-26 | Cytogen Corporation | Method for the preparation of antibody-fragment conjugates |
EP0398872A1 (en) * | 1988-02-12 | 1990-11-28 | HighTech Receptor AB | Immunoglobulin binding substance, subfragments, a process for preparing thereof, reagent kit and immunoglobulin binding organisms |
US4983529A (en) * | 1988-06-10 | 1991-01-08 | Abbott Laboratories | Immunoassay for HIV-I antigens using F(AB')2 fragments as probe |
KR900005995A (ko) * | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
JPH04504253A (ja) * | 1989-03-27 | 1992-07-30 | セントカー・インコーポレーテツド | IgM抗体の安定化のための配合物 |
-
1991
- 1991-06-28 CA CA002086531A patent/CA2086531A1/en not_active Abandoned
- 1991-06-28 KR KR1019920703408A patent/KR930701201A/ko not_active Application Discontinuation
- 1991-06-28 JP JP91511093A patent/JPH05507924A/ja active Pending
- 1991-06-28 WO PCT/EP1991/001223 patent/WO1992000763A1/en not_active Application Discontinuation
- 1991-06-28 EP EP91911923A patent/EP0537222A1/en not_active Withdrawn
- 1991-06-28 HU HU9204170A patent/HUT63343A/hu unknown
-
1992
- 1992-12-21 FI FI925804A patent/FI925804A/fi unknown
Also Published As
Publication number | Publication date |
---|---|
JPH05507924A (ja) | 1993-11-11 |
WO1992000763A1 (en) | 1992-01-23 |
CA2086531A1 (en) | 1992-01-04 |
HUT63343A (en) | 1993-08-30 |
FI925804A0 (fi) | 1992-12-21 |
EP0537222A1 (en) | 1993-04-21 |
HU9204170D0 (en) | 1993-04-28 |
FI925804A (fi) | 1992-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE128732T1 (de) | Antigenkonstrukte von ''major histocompatibility complex'' klasse i antigenen mit spezifischen trägermolekülen, ihre herstellung und verwendung. | |
DK0673255T3 (da) | Monoklonale antistoffer, som specifikt binder til vaskulært tumorendotel, og anvendelser deraf | |
BR9810907A (pt) | Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico | |
DE69807679D1 (de) | Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren | |
EP0683234A4 (en) | ANTIBODIES DIRECTED AGAINST -g (b) -AMYLOID OR A DERIVATIVE THEREOF AND ITS USE. | |
PT752876E (pt) | Anticorpos monoclonicos que se conectam com o percursor antigeneo de rejeicao de tumores mage-1, mage-1 recombinante, e peptidos imunogenicos derivados de mage-1 | |
DK0523395T3 (da) | Seroreaktive områder på proteinerne E1 og E2 i HPV 16 | |
ATE177758T1 (de) | Synthetische peptide, antikörper dagegen und ihre verwendung | |
KR900013986A (ko) | 종양-관련항원에 대한 모노클로날 항체(MAb_s), 이의 제조방법 및 용도 | |
Atassi et al. | Localization and verification by synthesis of five antigenic sites of bovine serum albumin | |
EP0722499A4 (en) | IMMUNOREACTIVE ANTIGENS OF HEPATITIS E VIRUS | |
DE3884316D1 (de) | Synthetische Peptide, gegen diese gerichtete Antikörper und deren Verwendung. | |
CA2137280A1 (fr) | Clonage du gene codant pour la proteine gp28.5 de toxoplasma gondii; fragments peptidiques de cette proteine et leurs applications | |
KR930701201A (ko) | 면역반응성 화합물 | |
ES2082132T3 (es) | Composicion que contiene al menos dos anticuerpos distintos o fragmentos de ellos. | |
NO972522L (no) | Monoklonale antistoffer med immunoundertrykkende aktivitet | |
Carding et al. | Multiple proteins related to the soluble galactose-binding animal lectin revealed by a monoclonal anti-lectin antibody | |
ATE345501T1 (de) | Elisa-serodiagnose von schweinepleuropneumonie des serotyps 2 | |
GB2299994A (en) | Equine arteritis virus peptides antibodies and their use in a diagnostic test | |
Stepanik et al. | Primary structure of human alpha 2-macroglobulin. III. Primary structure of three large disulfide-bridged CNBr fragments, located in the COOH-terminal part of alpha 2-macroglobulin and accounting for 301 residues. | |
Sanderson et al. | Interchange of Allospecific MHC Class 1 Peptide Chains with Xenospecific β2Microglobulin and its Implications for Genetic Restriction | |
KR890010191A (ko) | 만손주혈흡충에 대한 백신 | |
GB2333295A (en) | Modified protein G and fragments thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |